However, the sensitivity of PSMA PET/CT for the detection of lymph node metastases is moderate (33–91%), most likely due to the limitations in the spatial resolution to detect small (< 3 mm) lymph node tumour deposits in primary as well as recurrent prostate cancer [13]. This evidence concerns the gene FOLH1 and prostate cancer.